AI assistant
COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2021
Jan 21, 2021
32163_dirs_2021-01-21_44f0e9f4-3adc-447b-a09b-b3f4e1684d48.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2021-01-19
Reporting Person: Kuhlmann Shirley R. (EVP and General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-19 | Common Stock | A | 45360 | — | Acquired | 102891 | Direct |
| 2021-01-19 | Common Stock | A | 6772 | — | Acquired | 109663 | Direct |
| 2021-01-20 | Common Stock | S | 6081 | $24.45 | Disposed | 103582 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-19 | Stock Option (Right to Purchase) | $24.06 | A | 129600 | Acquired | 2031-01-19 | Common Stock (129600) | Direct |
Footnotes
F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
F2: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.
F4: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.